Caitlin Md Dugdale

Caitlin Md Dugdale

Auto-generated profile, based on publicly available information

Caitlin Md Dugdale

Medical Practice Evaluation Center, Massachusetts General Hospital , Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
CDCaitlin M. Dugdale
Caitlin M. Dugdale
RWRochelle P. Walensky
Rochelle P. Walensky
In March 2020, the soaring number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections resulted in an unprecedented shortage of personal p

7 May 2019 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
CDCaitlin M. Dugdale
Caitlin M. Dugdale
ACAndrea L. Ciaranello
Andrea L. Ciaranello
LBLinda-Gail Bekker
Linda-Gail Bekker
MSMadeline E. Stern
Madeline E. Stern
LMLandon Myer
Landon Myer
RWRochelle P. Walensky
Rochelle P. Walensky
Dolutegravir is superior to efavirenz for HIV antiretroviral therapy (ART) but may be associated with an increased risk for neural tube defects (NTDs) in newborns if used by women at conception. To project clinical outcomes of ART policies for women of child-bearing potential in South Africa. Model of 3 strategies: efavirenz for all women of child-bearing potential (EFV), dolutegravir for all women of child-bearing potential (DTG), or World Health Organization (WHO)-recommended efavirenz without contraception or dolutegravir with contraception (WHO approach). Published data on NTD risks (efavirenz, 0.05%; dolutegravir, 0.67% [Tsepamo study]), 48-week ART efficacy with initiation (efavirenz, 60% to 91%; dolutegravir, 96%), and age-stratified fertility rates (2 to 139 per 1000 women). 3.1 million South African women with HIV (aged 15 to 49 years) starting or continuing first-line ART, and their children. 5 years. Societal. EFV, DTG, and WHO approach. Deaths among women and children, sexual and pediatric HIV transmissions, and NTDs. Compared with EFV, DTG averted 13 700 women's deaths (0.44% decrease) and 57 700 sexual HIV transmissions, but increased total pediatric deaths by 4400 because of more NTDs. The WHO approach offered some benefits compared with EFV, averting 4900 women's deaths and 20 500 sexual transmissions while adding 300 pediatric deaths. Overall, combined deaths among women and children were lowest with DTG (358 000 deaths) compared with the WHO approach (362 800 deaths) or EFV (367 300 deaths). Women's deaths averted with DTG exceeded pediatric deaths added with EFV unless dolutegravir-associated NTD risk was 1.5% or greater. Uncertainty in NTD risks and dolutegravir efficacy in resource-limited settings, each examined in sensitivity analyses. Although NTD risks may be higher with dolutegravir than efavirenz, dolutegravir will lead to many fewer deaths among women, as well as fewer overall HIV transmissions. These results argue against a uniform policy of avoiding dolutegravir in women of child-bearing potential. National Institutes of Health, National Institute of Allergy and Infectious Diseases and Eunice Kennedy Shriver National Institute of Child Health and Human Development; Massachusetts General Hospital; and Harvard University Center for AIDS Research.

1 December 2020 in Radiology
Verified
Journal Article
Closed access
NJNicholos P. Joseph
Nicholos P. Joseph
NRNicholas J. Reid
Nicholas J. Reid
ASAvik Som
Avik Som
MLMatthew D. Li
Matthew D. Li
EHEmily P. Hyle
Emily P. Hyle
EFEfrén J. Flores
Efrén J. Flores
Background Disease severity on chest radiographs (CXR) has been associated with higher risk of disease progression and adverse outcomes from COVID-19. Few studies have evaluated COVID-19-related ra...

19 April 2016 in Aesthetic Surgery Journal
Verified
Journal Article
Closed access
PDF file
MSMansher Singh
Mansher Singh
CDCaitlin M. Dugdale
Caitlin M. Dugdale
ISIsaac H. Solomon
Isaac H. Solomon
AHAnne Huang
Anne Huang
MMMary W. Montgomery
Mary W. Montgomery
STSimon G. Talbot
Simon G. Talbot
Background “Medical tourism” has gained popularity over the past few decades. This is particularly common with patients seeking elective cosmetic surgery in the developing world. However, the risk of severe and unusual infectious complications appears to be higher than for patients undergoing similar procedures in the United States. Objectives The authors describe their experience with atypical mycobacterial infections in cosmetic surgical patients returning to the United States postoperatively. Methods A review of patient medical records presenting with infectious complications after cosmetic surgery between January 2010 and July 2015 was performed. Patients presenting with mycobacterial infections following cosmetic surgery were reviewed in detail. An extensive literature review was performed for rapid-growing mycobacteria (RGM) related to cosmetic procedures. Results Between January 2010 and July 2015, three patients presented to our institution with culture-proven Mycobacterium abscessus at the sites of recent cosmetic surgery. All had surgery performed in the developing world. The mean age of these patients was 36 years (range, 29-44 years). There was a delay of up to 16 weeks between the initial presentation and correct diagnosis. All patients were treated with surgical drainage and combination antibiotics with complete resolution. Conclusions We present series of patients with mycobacterial infections after cosmetic surgery in the developing world. This may be related to the endemic nature of these bacteria and/or inadequate sterilization or sterile technique. Due to low domestic incidence of these infections, diagnosis may be difficult and/or delayed. Consulting physicians should have a low threshold to consider atypical etiologies in such scenarios. Level of Evidence 5 Therapeutic

1 March 2019 in The Lancet HIV
Verified
Journal Article
Closed access
SFSimone C Frank
Simone C Frank
JCJennifer Cohn
Jennifer Cohn
LDLorna Dunning
Lorna Dunning
ESEmma Sacks
Emma Sacks
RWRochelle P Walensky
Rochelle P Walensky
ACAndrea L Ciaranello
Andrea L Ciaranello

15 July 2025 in The Lancet
Verified
Journal Article
Open access
CDCaitlin M Dugdale
Caitlin M Dugdale
OUOgochukwu Ufio
Ogochukwu Ufio
JGJohn Giardina
John Giardina
FSFatma Shebl
Fatma Shebl
ECElif Coskun
Elif Coskun
ACAndrea L Ciaranello
Andrea L Ciaranello
Although a growing body of evidence supports zero risk of sexual HIV transmission from a person with sustained virological suppression, known as U=U (undetectable equals untransmittable), data have been insufficient to determine whether this is also true for vertical HIV transmission. We conducted a systematic review and meta-analysis to quantify vertical transmission risk by maternal HIV viral load (mHVL) and to evaluate the applicability of U=U to perinatal and postnatal HIV transmission. In this systematic review and meta-analysis, we searched PubMed, Embase, Web of Science, Cochrane Library, Cumulative Index of Nursing and Allied Health Literature, the WHO Global Health Library, and abstracts from the International AIDS Society Conference and the Conference on Retroviruses and Opportunistic Infections (2016-24) for studies published from Jan 1, 1989, to Dec 31, 2024, reporting the relationship between mHVL near birth (to estimate perinatal transmission risk by 6 weeks) or during breastfeeding (to estimate monthly postnatal transmission risk by mHVL within the past 6 months) and vertical transmission. We pooled risks of perinatal and postnatal transmission across prespecified mHVL categories. We also conducted comparative analyses to determine the adjusted relative risk (aRR) of transmission by mHVL using Poisson meta-regression. The protocol for this analysis is registered on the International Prospective Register of Systematic Reviews (PROSPERO; CRD42019146768). 147 studies were included in the analysis; 138 studies contributed to perinatal analyses and 13 studies contributed to postnatal analyses. Data on 82 723 mother-child pairs were included across all analyses. Pooled perinatal transmission risks were 0·2% (95% CI 0·2-0·3) with a mHVL of <50 copies per mL, 1·3% (1·0-1·7) with 50-999 copies per mL, and 5·1% (2·6-7·9) with ≥1000 copies per mL. aRRs of perinatal transmission were 6·3 (3·9-10·3) with a mHVL of 50-999 copies per mL and 22·5 (13·9-36·5) with ≥1000 copies per mL versus <50 copies per mL. In subgroup analyses, in five studies reporting on 4675 women receiving pre-conception antiretroviral therapy (ART) with a mHVL of <50 copies per mL near birth, there were zero (0%, 0·0-0·1) perinatal transmissions. Monthly postnatal transmission risks were 0·1% (0·0-0·4) with recent mHVL <50 copies per mL and 0·5% (0·1-1·8) with a mHVL of ≥50 copies per mL. Perinatal transmission with a mHVL of <50 copies per mL is ≤0·2% overall. Zero transmissions were observed among women receiving ART before pregnancy with a mHVL of <50 copies per mL near birth, supporting U=U in pregnancy and birth. Postnatal transmission was very low-but not zero-among women with a recent mHVL of <50 copies per mL. Current data, largely from studies lacking frequent mHVL monitoring or modern first-line ART regimens, are insufficient to assess U=U during breastfeeding. National Institutes of Health, WHO, and Massachusetts General Hospital.